Company profile: Lumicell
1.1 - Company Overview
Company description
- Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
Products and services
- LUMISIGHT (pegulicianine): An optical imaging agent that, when paired with the Lumicell DVS, highlights residual cancerous tissue during lumpectomy for real-time visualization
- Lumicell Direct Visualization System (DVS): A fluorescence-guided imaging system engineered to detect residual cancerous tissue in real-time during lumpectomy surgery
- Image-Guided Cancer Surgery Systems: Image-guided products that support real-time detection and visualization of residual cancerous tissue during lumpectomy by combining Lumicell DVS with LUMISIGHT (pegulicianine)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lumicell
Abingdon Health
HQ: United Kingdom
Website
- Description: Provider of rapid and near-patient medical diagnostic testing solutions as an innovative, technology-led company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abingdon Health company profile →
Intact Medical
HQ: United States
Website
- Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intact Medical company profile →
Argos Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Conducts clinical trial programs in cancer and HIV. Product candidates include AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, and CD83.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argos Therapeutics company profile →
Pheon Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheon Therapeutics company profile →
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lumicell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lumicell
2.2 - Growth funds investing in similar companies to Lumicell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lumicell
4.2 - Public trading comparable groups for Lumicell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →